Belite Bio (BLTE) EBIT (2022 - 2026)

Belite Bio's EBIT history runs 5 years deep, the most recent figure standing at -$32.7 million for Q1 2026.

• In Q1 2026, EBIT rose 100.0% year-over-year to -$32.7 million; the TTM figure through Mar 2026 stood at -$17.6 billion (up 99.89% YoY), while the FY2025 annual figure was -$84.2 million, down 110.54% from the prior year.
• EBIT for Q1 2026 stood at -$32.7 million, down from -$28077.0 in the prior quarter.
• The five-year high for EBIT was -$23018.0 in Q3 2025, with the low at -$15517.0 billion in Q1 2025.
• The 5-year median for EBIT is -$7.6 billion (2023), against an average of -$1829.3 billion.
• The sharpest annual moves came in 2025 and 2026: EBIT slumped 186223.25% in 2025, then surged 100.0% in 2026.
• Belite Bio's EBIT stood at -$6721.0 billion in 2022, then dropped by 3.48% to -$6955.0 billion in 2023, then soared by 99.84% to -$11.5 billion in 2024, then surged by 100.0% to -$28077.0 in 2025, then sank by 116308.45% to -$32.7 million in 2026.
• Business Quant data shows BLTE's EBIT at -$32.7 million in Q1 2026, -$28077.0 in Q4 2025, and -$23018.0 in Q3 2025.